16 October 2020>: Clinical Research
Single Large Nodule (>5 cm) Prognosis in Hepatocellular Carcinoma: Kinship with Barcelona Clinic Liver Cancer (BCLC) Stage A or B?
Li Wan 12BCDE , Ding-Hui Dong 1ABCDE , Xiao-Ning Wu 1BCD , Hong-Fan Ding 1BCD , Qiang Lu 1BCD , Yong Tian 2BC , Xu-Feng Zhang 1ABCDEFG* , Wenzhi Li 13ADE*DOI: 10.12659/MSM.926797
Med Sci Monit 2020; 26:e926797
Table 1 Characteristics of the patients with hepatocellular carcinoma in BCLC stages A1, A2, and B.
Variables | BCLC stages A1 (n=455) | BCLC stage A2 (n=188) | BCLC stage B (n=362) |
---|---|---|---|
Male sex | 366 (80.4%) | 154 (81.9%) | 292 (80.7%) |
Age (years) | 55 (24–82) | 54 (22–82) | 55 (13–87) |
History of cigarette smoking | 188 (41.3%) | 87 (46.3%) | 151 (41.7%) |
History of alcohol abuse | 145 (31.9%) | 65 (34.6%) | 113 (31.2%) |
Diabetes# | 42 (9.2%) | 22 (11.7%) | 18 (5.0%) |
HBV positivity | 338 (74.2%) | 133 (70.7%) | 249 (68.8%) |
HCV positivity | 34 (7.5%) | 7 (3.7%) | 16 (4.4%) |
Liver cirrhosis | 314 (69.0%) | 121 (64.4%) | 229 (63.3%) |
Child-Pugh class B# | 31 (6.8%) | 19 (10.1%) | 15 (4.1%) |
AFP >200 ng/ml | 222 (48.8%) | 109 (58.0%) | 186 (51.4%) |
Primary treatments | |||
Surgical resection | 155 (34.1%) | 49 (26.1%) | 130 (35.9%) |
Radiofrequency ablation* | 129 (28.4%) | 32 (17.0%) | 43 (11.9%) |
TACE* | 148 (32.5%) | 86 (45.7%) | 159 (43.9%) |
Supportive treatments* | 23 (5.1%) | 21 (11.1%) | 30 (8.3%) |
30-day mortality | 17 (3.7%) | 8 (4.3%) | 10 (2.8%) |
90-day mortality | 28 (6.2%) | 14 (7.4%) | 30 (8.3%) |
HCC – hepatocellular carcinoma; BCLC – Barcelona Clinic Liver Cancer; HBV – hepatitis B virus; HCV – hepatitis C virus; AFP – alpha-fetoprotein; TACE – transarterial chemoembolization. * # |